Latest news

• GSK files anaemia drug daprodustat in Japan, its first market

  Daprodustat – a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) – will be distributed in Japan by Kyowa Kirin if it gets the nod from the Ministry of Health, Labour and Welfare ... In contrast, HIF-PHI drugs stimulate endogenous

• China first market to approve AZ’s kidney drug roxadustat

  Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and according to AZ’s chief medical officer Sean Bohen is the first oral drug in this class, as well ... In contrast,   HIF-PH inhibitors stimulate endogenous production

• GSK starts late-stage trials of daprodustat

  CKD)  . The orally-active hypoxia-inducible prolyl hydroxylase inhibitor (HIF-PHI) could be a $450m product by 2020, according to Credit Suisse forecasts, and is one of a block of new ... administration.". GSK is in a race to market with other HIF-PHI

• AZ inks $815m deal for FibroGen anaemia drug

  The drug is an orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) and offers an alternative to injectable treatments based on erythropoietin (EPO), which account for